[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nuvation Bio Inc (NUVB)

Nuvation Bio Inc (NUVB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes

NEW YORK , June 25, 2026 Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced the pricing...

NUVB : 5.70 (+5.17%)
Nuvation Bio Announces Proposed Convertible Senior Notes Offering

NEW YORK , June 25, 2026 /PRNewswire/ -- Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today...

NUVB : 5.70 (+5.17%)
Nuvation Bio to Present at the Jefferies Global Healthcare Conference

NEW YORK , May 27, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David...

NUVB : 5.70 (+5.17%)
Nuvation Bio to Present New Quality-of-Life Data for IBTROZI® (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual Meeting

  88% of TRUST-II patients reported improved or stable quality of life at first assessment, with the majority sustaining that benefit throughout treatment

NUVB : 5.70 (+5.17%)
Nuvation Bio to Collaborate with Thermo Fisher Scientific for U.S.-Based Manufacturing of IBTROZI® for ROS1-Positive Non-Small Cell Lung Cancer

Thermo Fisher Scientific, the world leader in serving science, will now manufacture drug product for Nuvation Bio in the United States

NUVB : 5.70 (+5.17%)
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Nuvation Bio Inc. (NYSE: NUVB)

NEW YORK , May 7, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Nuvation Bio Inc. (NYSE: NUVB) on behalf of the company's shareholders. The investigation seeks to...

NUVB : 5.70 (+5.17%)
Nuvation Bio to Participate in Upcoming Investor Conferences

NEW YORK , May 5, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David...

NUVB : 5.70 (+5.17%)
Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update

Achieved $18.5 million in first quarter of 2026 net product revenues for IBTROZI ® (taletrectinib); majority of the approximately 200 patients started on IBTROZI in the first...

NUVB : 5.70 (+5.17%)
Can Nuvation Bio's Pipeline Finally Prove the Skeptics Wrong About Its Valuation?

Barchart Research What to Expect from NUVB Earnings NUVB Generated May 1, 2026 Current Price $4.49 EPS Estimate $$0.12 Consensus Rating Strong Buy Average Move 6.61% Can Nuvation Bio's Pipeline Finally...

NUVB : 5.70 (+5.17%)
Can Nuvation Bio's Pipeline Finally Prove the Skeptics Wrong About Its Valuation?

Barchart Research What to Expect from NUVB Earnings NUVB Generated May 1, 2026 Current Price $4.49 EPS Estimate $$0.12 Consensus Rating Strong Buy Average Move 6.61% Can Nuvation Bio's Pipeline Finally...

NUVB : 5.70 (+5.17%)

Barchart Exclusives

FedEx Is Abandoning Its Supply Chain Business. FDX Stock Investors Need the Logistics Giant to Protect Its Core Network.
FedEx is selling FedEx Supply Chain to shipping giant CMA CGM for $1.4 billion, narrowing its focus to premium B2B shipping, logistics, and freight moves. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.